NCT01561313View on ClinicalTrials.gov

Crossover Study of Safety and Tolerability of Two Formulations of Adalimumab.

PHASE2CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2012

Conditions
Rheumatoid Arthritis
Interventions
BIOLOGICAL

Adalimumab

Subcutaneously 40 mg every other week (EOW) or every week (EW) (as dosing requires)

Trial Locations (6)

3600

Site Reference ID/Investigator# 63357, Genk

9000

Site Reference ID/Investigator# 63359, Ghent

Site Reference ID/Investigator# 63360, Ghent

63800

Site Reference ID/Investigator# 63363, Brno

128 50

Site Reference ID/Investigator# 63362, Prague

686 01

Site Reference ID/Investigator# 63361, Uherské Hradiště

All Listed Sponsors
lead

AbbVie (prior sponsor, Abbott)

INDUSTRY

NCT01561313 - Crossover Study of Safety and Tolerability of Two Formulations of Adalimumab. | Biotech Hunter | Biotech Hunter